LT3440106T - T ląstelių receptoriai - Google Patents

T ląstelių receptoriai

Info

Publication number
LT3440106T
LT3440106T LTEPPCT/EP2017/058580T LTEP2017058580T LT3440106T LT 3440106 T LT3440106 T LT 3440106T LT EP2017058580 T LTEP2017058580 T LT EP2017058580T LT 3440106 T LT3440106 T LT 3440106T
Authority
LT
Lithuania
Prior art keywords
cell receptors
receptors
cell
Prior art date
Application number
LTEPPCT/EP2017/058580T
Other languages
English (en)
Inventor
Nicholas TRIBBLE
William Lawrance
Eleanor BAGG
Original Assignee
Adaptimmune Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adaptimmune Limited filed Critical Adaptimmune Limited
Publication of LT3440106T publication Critical patent/LT3440106T/lt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/7051T-cell receptor (TcR)-CD3 complex
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14Blood; Artificial blood
    • A61K35/17Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/461Cellular immunotherapy characterised by the cell type used
    • A61K39/4611T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/463Cellular immunotherapy characterised by recombinant expression
    • A61K39/4632T-cell receptors [TCR]; antibody T-cell receptor constructs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/464Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643Vertebrate antigens
    • A61K39/4644Cancer antigens
    • A61K39/464484Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/464486MAGE
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0636T lymphocytes
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
LTEPPCT/EP2017/058580T 2016-04-08 2017-04-10 T ląstelių receptoriai LT3440106T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB201606177 2016-04-08
PCT/EP2017/058580 WO2017174824A1 (en) 2016-04-08 2017-04-10 T cell receptors

Publications (1)

Publication Number Publication Date
LT3440106T true LT3440106T (lt) 2021-12-10

Family

ID=58701592

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/EP2017/058580T LT3440106T (lt) 2016-04-08 2017-04-10 T ląstelių receptoriai

Country Status (24)

Country Link
US (3) US11286289B2 (lt)
EP (2) EP3440106B1 (lt)
JP (2) JP7240176B2 (lt)
KR (2) KR102523449B1 (lt)
CN (2) CN109476725B (lt)
AU (2) AU2017248122B2 (lt)
BR (1) BR112018070625A2 (lt)
CA (1) CA3020058A1 (lt)
CY (1) CY1124664T1 (lt)
DK (1) DK3440106T3 (lt)
ES (1) ES2891321T3 (lt)
HR (1) HRP20211493T1 (lt)
HU (1) HUE056433T2 (lt)
IL (1) IL262128A (lt)
LT (1) LT3440106T (lt)
MX (2) MX2018012269A (lt)
PL (1) PL3440106T3 (lt)
PT (1) PT3440106T (lt)
RS (1) RS62623B1 (lt)
RU (1) RU2018138838A (lt)
SG (1) SG11201808751SA (lt)
SI (1) SI3440106T1 (lt)
WO (1) WO2017174824A1 (lt)
ZA (1) ZA201806866B (lt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20211327T1 (hr) 2014-12-23 2022-01-21 Immatics Biotechnologies Gmbh Novi peptidi i kombinacije peptida za upotrebu u imunoterapiji protiv hepatocelularnog karcinoma (hcc) i drugih rakova
GB201501017D0 (en) 2014-12-23 2015-03-04 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
KR20190065189A (ko) * 2016-04-08 2019-06-11 어댑티뮨 리미티드 T 세포 수용체
CN117603339A (zh) * 2016-04-08 2024-02-27 艾达普特免疫有限公司 T细胞受体
MX2018012269A (es) 2016-04-08 2019-05-30 Adaptimmune Ltd Receptores de celulas t.
KR20200063215A (ko) 2017-10-06 2020-06-04 오슬로 유니버시테시케후스 에이치에프 키메라 항원 수용체
CN109777778B (zh) * 2017-11-14 2023-07-18 中国科学院广州生物医药与健康研究院 一种基因改造的γδT细胞
GB201803750D0 (en) 2018-03-08 2018-04-25 Immunocore Ltd Method
EP3714941A1 (en) * 2019-03-27 2020-09-30 Medigene Immunotherapies GmbH Mage-a4 tcrs
CN114585646A (zh) * 2019-06-18 2022-06-03 里珍纳龙药品有限公司 Mage-a4 t细胞受体及其使用方法
CA3142513A1 (en) 2019-06-25 2020-12-30 Gilead Sciences, Inc. Flt3l-fc fusion proteins and methods of use
US20230000913A1 (en) 2019-08-13 2023-01-05 King's College London Immunoresponsive cells armoured with spatiotemporally restricted activity of cytokines of the il-1 superfamily
EP4076666A1 (en) 2019-12-18 2022-10-26 F. Hoffmann-La Roche AG Antibodies binding to hla-a2/mage-a4
CN117964757A (zh) 2020-02-14 2024-05-03 吉利德科学公司 与ccr8结合的抗体和融合蛋白及其用途
TWI815194B (zh) 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
KR20230169944A (ko) 2021-03-09 2023-12-18 씨디알-라이프 아게 Mage-a4 펩티드-mhc 항원 결합 단백질
TW202313094A (zh) 2021-05-18 2023-04-01 美商基利科學股份有限公司 使用FLT3L—Fc融合蛋白之方法
EP4091627A1 (en) 2021-05-21 2022-11-23 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft Tcr constructs specific for magea4-derived epitopes
WO2023076863A2 (en) * 2021-10-25 2023-05-04 Board Of Regents, The University Of Texas System Peptides and engineered t cell receptors targeting mage-a4 antigen and methods of use
TW202330504A (zh) 2021-10-28 2023-08-01 美商基利科學股份有限公司 嗒𠯤—3(2h)—酮衍生物
US11919869B2 (en) 2021-10-29 2024-03-05 Gilead Sciences, Inc. CD73 compounds
US20230242508A1 (en) 2021-12-22 2023-08-03 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
WO2023122581A2 (en) 2021-12-22 2023-06-29 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Parp7抑制劑
TW202346277A (zh) 2022-03-17 2023-12-01 美商基利科學股份有限公司 Ikaros鋅指家族降解劑及其用途
GB202205572D0 (en) 2022-04-14 2022-06-01 Adaptimmune Ltd Engineered T cells
TW202400138A (zh) 2022-04-21 2024-01-01 美商基利科學股份有限公司 Kras g12d調節化合物
WO2024006929A1 (en) 2022-07-01 2024-01-04 Gilead Sciences, Inc. Cd73 compounds
AU2023241307A1 (en) * 2022-10-05 2024-05-02 Tscan Therapeutics Inc Magea1 immunogenic peptides, binding proteins recognizing magea1 immunogenic peptides, and uses thereof
AU2023241306A1 (en) * 2022-10-05 2024-05-02 Tscan Therapeutics Inc Prame immunogenic peptides, binding proteins recognizing prame immunogenic peptides, and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0869943A1 (en) * 1995-12-08 1998-10-14 Smithkline Beecham Plc Monocyclic beta-lactame derivatives for treatment of atherosclerosis
WO2000020445A2 (en) 1998-10-02 2000-04-13 Ludwig Institute For Cancer Research Tumor antigens and ctl clones isolated by a novel procedure
US7157091B1 (en) 1999-06-18 2007-01-02 Ludwig Institute For Cancer Research MAGE-A1 peptides presented by HLA class II molecules
US6867283B2 (en) 2001-05-16 2005-03-15 Technion Research & Development Foundation Ltd. Peptides capable of binding to MHC molecules, cells presenting such peptides, and pharmaceutical compositions comprising such peptides and/or cells
US7049413B2 (en) 2001-05-18 2006-05-23 Ludwig Institute For Cancer Research MAGE-A3 peptides presented by HLA class II molecules
IL160359A0 (en) 2001-08-31 2004-07-25 Avidex Ltd Soluble t cell receptor
RU2355703C2 (ru) 2002-10-09 2009-05-20 Медиджен Лимитед Одноцепочечные рекомбинантные т-клеточные рецепторы
GB0304068D0 (en) 2003-02-22 2003-03-26 Avidex Ltd Substances
US8003770B2 (en) * 2005-09-13 2011-08-23 Mie University T-cell receptor and nucleic acid encoding the receptor
US9586997B2 (en) 2010-09-20 2017-03-07 Biontech Cell & Gene Therapies Gmbh Antigen-specific T cell receptors and T cell epitopes
JP2015502915A (ja) * 2011-10-14 2015-01-29 テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド CD1dに対する抗体
KR20190065189A (ko) 2016-04-08 2019-06-11 어댑티뮨 리미티드 T 세포 수용체
CN117603339A (zh) 2016-04-08 2024-02-27 艾达普特免疫有限公司 T细胞受体
MX2018012269A (es) 2016-04-08 2019-05-30 Adaptimmune Ltd Receptores de celulas t.

Also Published As

Publication number Publication date
EP3988565A1 (en) 2022-04-27
AU2017248122B2 (en) 2022-07-21
KR102523449B1 (ko) 2023-04-19
WO2017174824A1 (en) 2017-10-12
RU2018138838A3 (lt) 2020-07-30
EP3440106B1 (en) 2021-09-01
US20220031753A1 (en) 2022-02-03
SG11201808751SA (en) 2018-11-29
CN109476725A (zh) 2019-03-15
MX2022011309A (es) 2022-10-07
SI3440106T1 (sl) 2022-02-28
US20230028573A1 (en) 2023-01-26
PL3440106T3 (pl) 2022-01-31
KR20230044016A (ko) 2023-03-31
RU2018138838A (ru) 2020-05-14
ES2891321T3 (es) 2022-01-27
CA3020058A1 (en) 2017-10-12
BR112018070625A2 (pt) 2019-02-05
US11286289B2 (en) 2022-03-29
AU2017248122A1 (en) 2018-11-22
US20190127436A1 (en) 2019-05-02
AU2022256177A1 (en) 2022-11-24
CY1124664T1 (el) 2022-07-22
US11572400B1 (en) 2023-02-07
JP2023081949A (ja) 2023-06-13
EP3440106A1 (en) 2019-02-13
HRP20211493T1 (hr) 2022-01-21
US11725040B2 (en) 2023-08-15
PT3440106T (pt) 2021-09-29
MX2018012269A (es) 2019-05-30
HUE056433T2 (hu) 2022-02-28
JP7240176B2 (ja) 2023-03-15
CN116217703A (zh) 2023-06-06
KR20190065190A (ko) 2019-06-11
CN109476725B (zh) 2023-04-04
DK3440106T3 (da) 2021-10-04
IL262128A (en) 2018-11-29
ZA201806866B (en) 2021-04-28
RS62623B1 (sr) 2021-12-31
JP2019513383A (ja) 2019-05-30

Similar Documents

Publication Publication Date Title
IL262144A (en) t cell receptors
ZA201806866B (en) T cell receptors
ZA201806862B (en) T cell receptors
IL271435A (en) t cell receptors
ZA201806865B (en) T cell receptors
IL264425B1 (en) t cell receptors against kras-g20
IL251524B (en) t cell receptors
GB201522592D0 (en) T cell receptors
RS64952B1 (sr) T ćelijski receptori
GB201518991D0 (en) T cell receptors